A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
May 22, 2018
End Date
February 29, 2024
Administered By
Duke Cancer Institute
Awarded By
AbbVie Inc.
Start Date
May 22, 2018
End Date
February 29, 2024